Casi
Fleet Management · Leasing, Auto & Equipment Finance
Overview
Casi is the platform for OEMs and FleetCos to launch, scale, and profit from flexible leasing and fleet services—powered by tech, services, and financing.
Funding and backers
Team
11-50
employees, estimated range
Backers
2
Idekapital, Norselab
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2018
Founded
Tractionpublic signals, read monthly
Web presence
top 7%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
FleetPartners is one of Australia's leading providers of passenger, commercial and heavy commercial vehicle leasing and fleet management.
Pelikan Mobility is a French startup offering long-term leasing dedicated to electric commercial vans. Founded in 2023, it combines a…
Evera is a French startup combining fleet management software with vehicle leasing for company cars, covering costs, total cost of…
Wheels is a fleet management company with customer service and business development roles for fleet billing and its truck and equipment…
Start your Fleet's. Electrification of your fleet will also transform your profitability and customer experience through significantly…
Do not let equipment leasing and equipment financing be slow and painful. LeaseQ makes it easy to get instant Equipment Lease Quotes from…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
NorselabVia a fund
IdekapitalVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
SOUTH SAN FRANCISCO, CA/ ACCESS Newswire/ February 25, 2026/ CASI Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant
Read more
Report
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
U.S. IND previously approved by FDA for Phase 1 AMR study. SOUTH SAN FRANCISCO, CALIFORNIA/ ACCESS Newswire/ January 15, 2026/ CASI Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing CID-103, a potentially best-in-class, anti-CD3
Read more
Report
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
CASI Pharmaceuticals, Inc. (Nasdaq:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the developmen ...
Read more
Report
Anitta Welcomes Fans Into Her New EP's World With The Colorful Music Video For 'Casi Casi'
Anitta has dropped her new 'Casi Casi' music video.
Read more
Report
Coronavirus: "Il 50-75% dei casi a Vo' sono asintomatici. Una formidabile fonte di contagio"
Lettera dell
Read more
Report
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company that is focusing on developing and accelerating the launch of...
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Bergen
Norway
HQ
10-50 est. staff